COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC:
Get the latest research information from NIH:

Coronavirus Guidance for NIH Applicants and Grantees:

Dr. Lilia Topol

Dr. Lilia Topol

Scientific Review Officer


Division of Translational and Clinical Sciences DTCS
Oncology 2 – Translational Clinical OTC
Study Section:
Cancer Drug Development and Therapeutics SBIR OTC-T 10-14

Dr. Lilia Topol is the Scientific Review Officer for the Cancer Drug Development and Therapeutics Small Business SBIR/STTR Special Emphasis Panel.

She came to CSR from the National Human Genome Research Institute at NIH, where she was a staff scientist for the last ten years. Prior this, she worked at the National Cancer Institute. Dr. Topol is a graduate of the Moscow State University with a bachelor degree in physiology, and she has a Ph.D. in oncology from the Cancer Research Center in Moscow. She came to NIH under the American Cancer Society International Fellowship, and her research was focused on signal transduction pathways regulated by oncogenes in cancer development. She then studied the molecular mechanisms that regulate the normal and malignant cell phenotypes. Dr. Topol co-discovered a new gene, DRM/Gremlin that belongs to the family of bone morphogenic protein antagonists.